Abstract
Juvenile idiopathic arthritis (JIA) is one of the most frequent autoimmune diseases in childhood and is characterized by chronic inflammation of the synovial fluid in joints. Several drugs are available for the treatment of JIA, including various biological agents that interfere with critical cytokine pathways. Though very effective in suppressing disease activity, none of these drugs can cure the disease and induce a lasting medication free remission. A small proportion of JIA patients will become or are unresponsive to any form of medical treatment. For these severely ill patients autologous bone marrow transplantation (aBMT) is a last resort treatment. aBMT is remarkably effective in suppressing disease activity, with beneficial outcome reported in around 70% of these previously refractory patients. Moreover aBMT is the only treatment that can induce a lasting medication-free-disease remission in these patients. In the very long term (after 7 years of remission) however, some disease relapses are observed, with the disease returning in a less severe form compared to prior aBMT. The exact mechanism of how aBMT is inducing this lasting disease remission is still largely unknown, but data from both animal models and humans suggest a prominent role for regulatory T cells.
In this review we reviewed the current views of the cellular mechanisms that lay beneath disease induction of JIA and the disease remission caused by aBMT therapy.
Keywords: Juvenile idiopathic arthritis, autologous bone marrow transplantation, regulatory T cells, T helper 17 cells, autoimmune diseases, synovial fluid, cytokine, rheumatic diseases, arthritis, anorexia, spiking fever, hepatosplenomegaly, non-steroidal anti-inflammatory drugs, disease modifying drugs, anti-interleukin 1, anti-interleukin 6, anti-TNF, CD4, glucocorticoid-induced tumor necrosis factor receptor (GITR), FOXP3, peripheral immune system, im-mune dysregulation, polyendocrinopathy, enterpathy, homeosta-sis, autoimmunity, immunopathogenesis, Experimental Autoimmune Enceohalomyelitis, Multiple Sclerosis (MS), Systemic Lupus Erythematosus, chemotherapy, lymphocytes, macrophage activation syn-drome, Varicella Zoster Virus, Epstein Barr virus, Cytomegalie Virus, disseminated Adenovirus reactivation, corticosteroids, immunobiology, phenotype, proteo-glycan, proteoglycan induced ar-thritis (PGIA), histopathological resemblance, polyarthritis, immune tolerance, white blood cell count (WBC), anti-CD25 monoclonal antibody, immunologi-cal mechanism
Current Stem Cell Research & Therapy
Title: Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Volume: 6 Issue: 1
Author(s): Eveline Delemarre, Sarah Roord, Nico Wulffraat, Femke van Wijk and Berent Prakken
Affiliation:
Keywords: Juvenile idiopathic arthritis, autologous bone marrow transplantation, regulatory T cells, T helper 17 cells, autoimmune diseases, synovial fluid, cytokine, rheumatic diseases, arthritis, anorexia, spiking fever, hepatosplenomegaly, non-steroidal anti-inflammatory drugs, disease modifying drugs, anti-interleukin 1, anti-interleukin 6, anti-TNF, CD4, glucocorticoid-induced tumor necrosis factor receptor (GITR), FOXP3, peripheral immune system, im-mune dysregulation, polyendocrinopathy, enterpathy, homeosta-sis, autoimmunity, immunopathogenesis, Experimental Autoimmune Enceohalomyelitis, Multiple Sclerosis (MS), Systemic Lupus Erythematosus, chemotherapy, lymphocytes, macrophage activation syn-drome, Varicella Zoster Virus, Epstein Barr virus, Cytomegalie Virus, disseminated Adenovirus reactivation, corticosteroids, immunobiology, phenotype, proteo-glycan, proteoglycan induced ar-thritis (PGIA), histopathological resemblance, polyarthritis, immune tolerance, white blood cell count (WBC), anti-CD25 monoclonal antibody, immunologi-cal mechanism
Abstract: Juvenile idiopathic arthritis (JIA) is one of the most frequent autoimmune diseases in childhood and is characterized by chronic inflammation of the synovial fluid in joints. Several drugs are available for the treatment of JIA, including various biological agents that interfere with critical cytokine pathways. Though very effective in suppressing disease activity, none of these drugs can cure the disease and induce a lasting medication free remission. A small proportion of JIA patients will become or are unresponsive to any form of medical treatment. For these severely ill patients autologous bone marrow transplantation (aBMT) is a last resort treatment. aBMT is remarkably effective in suppressing disease activity, with beneficial outcome reported in around 70% of these previously refractory patients. Moreover aBMT is the only treatment that can induce a lasting medication-free-disease remission in these patients. In the very long term (after 7 years of remission) however, some disease relapses are observed, with the disease returning in a less severe form compared to prior aBMT. The exact mechanism of how aBMT is inducing this lasting disease remission is still largely unknown, but data from both animal models and humans suggest a prominent role for regulatory T cells.
In this review we reviewed the current views of the cellular mechanisms that lay beneath disease induction of JIA and the disease remission caused by aBMT therapy.
Export Options
About this article
Cite this article as:
Delemarre Eveline, Roord Sarah, Wulffraat Nico, van Wijk Femke and Prakken Berent, Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis, Current Stem Cell Research & Therapy 2011; 6 (1) . https://dx.doi.org/10.2174/157488811794480726
DOI https://dx.doi.org/10.2174/157488811794480726 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Antibody - Fc Receptor Interactions in Antimicrobial Functions
Current Immunology Reviews (Discontinued) Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Modern Therapeutic Strategies for Autoimmune Diseases
Current Pharmaceutical Design Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy The Role of Autophagy in Rheumatic Disease
Current Drug Targets Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry